在阿尔茨海默病中ACHE抑制剂的演变:从单向多向向向向
Namrashee V Mehta1, Akshay Kapadia2, Mihir Khambete3
1Program in Chemical Biology, University of Michigan, Ann Arbor, Michigan, 48108, USA.
Chembiochem : a European journal of chemical biology
|July 28, 2025
概括
本综述追踪了阿尔茨海默病 (AD) 的乙胆酶抑制剂从单向药物到多向连接体 (MTDL) 的演变. 通过解决复杂的病理,MTDL显示出更有效的AD治疗的前景.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 药物发现 药物发现 药物发现
背景情况:
- 阿尔茨海默病 (AD) 是一种神经退行性疾病,其特点是认知能力下降,神经炎症和标志性蛋白质聚合物.
- 目前的治疗方法,如乙胆酶抑制剂 (AChEIs),只能提供症状缓解,不能阻止疾病的进展.
研究的目的:
- 对阿尔茨海默病 (AD) 的乙胆酶抑制剂 (AChEIs) 从单向药物到多向配体 (MTDLs) 的发展进行审查.
- 要突出结构修改增强目标特异性,血脑屏障透和MTDLs的治疗疗效.
- 讨论MTDLs在开发新型抗阿尔茨海默病疗法的潜力和陷.
主要方法:
- 文献综述,重点关注AD研究中ACHEI的演变.
- 分析结构变化及其对药理性质的影响.
- 对复杂的AD病理学的MTDL策略的探索.
主要成果:
- 单一向的ACHEI在阻止AD进展方面具有有限的有效性.
- MTDLs代表了一个先进的治疗策略,同时针对多个AD相关途径.
- 对MTDL的结构优化可以改善关键的药理动力学和药理动力学特性.
结论:
- MTDLs为开发更有效的阿尔茨海默病治疗方法提供了一个有希望的途径.
- 对MTDL的进一步研究对于克服当前单一向疗法的局限性至关重要.
- 需要仔细考虑潜在的陷,才能在AD中成功开发MTDL.
更多相关视频
06:40Quantitative Measurement of γ-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms
Published on: January 25, 2018
6.9K
06:52Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
Published on: July 6, 2019
9.4K
相关概念视频
01:22Alzheimer's Disease: Treatment
262
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
262
01:29Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
654
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
654
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
2.0K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
2.0K
01:26Alzheimer's Disease: Overview
669
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
669
01:30Ligand-Gated Ion Channel Receptor: Gating Mechanism
2.6K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
2.6K
01:19Ligand-gated Ion Channels
12.7K
Ligand-gated ion channels are transmembrane proteins with a channel for ions to pass through and a binding site for a ligand. The channel opens only when a ligand attaches to the binding site.
Three Subfamilies of Ligand-gated Ion Channels
Ligand-gated ion channels fall into three subfamilies. The 'Cys-loop' includes the nicotinic acetylcholine receptors, γ-aminobutyric acid (GABA), glycine, and 5-hydroxytryptamine receptors. The second one is the 'Pore-loop' channels that...
Three Subfamilies of Ligand-gated Ion Channels
Ligand-gated ion channels fall into three subfamilies. The 'Cys-loop' includes the nicotinic acetylcholine receptors, γ-aminobutyric acid (GABA), glycine, and 5-hydroxytryptamine receptors. The second one is the 'Pore-loop' channels that...
12.7K